| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = -$92,313 ) |
| | 2024 | 2023 | CAMINO PHARMA, LLC | 7161 ROCK VALLEY CT | SAN DIEGO | CA | 92122-2737 | SAN DIEGO | USA | U43AA031388 | Preclinical validation of mGlu2 PAMs in alcohol use disorder | 000 | 1 | NIH | 10/26/2023 | $0 |
| | 2024 | 2021 | CAMINO PHARMA LLC | 7161 ROCK VALLEY CT | SAN DIEGO | CA | 92122-2737 | SAN DIEGO | USA | R43MH122063 | Negative Allosteric Modulators (NAMs) of Metabotropic Glutamate Receptors 2 & 3 (mGlu2/3) for the Treatment of Depression | 000 | 2 | NIH | 12/14/2023 | -$92,313 |
|
| Issue Date FY: 2023 ( Subtotal = $973,938 ) |
| | 2023 | 2023 | CAMINO PHARMA, LLC | 7161 ROCK VALLEY CT | SAN DIEGO | CA | 92122-2737 | SAN DIEGO | USA | U43AA031388 | Preclinical validation of mGlu2 PAMs in alcohol use disorder | 000 | 1 | NIH | 9/20/2023 | $973,938 |
|
| Issue Date FY: 2021 ( Subtotal = $449,453 ) |
| | 2021 | 2021 | CAMINO PHARMA, LLC | 7161 ROCK VALLEY CT | SAN DIEGO | CA | 92122-2737 | SAN DIEGO | USA | R43MH122063 | Negative Allosteric Modulators (NAMs) of Metabotropic Glutamate Receptors 2 & 3 (mGlu2/3) for the Treatment of Depression | 000 | 2 | NIH | 6/24/2021 | $449,453 |
|
| Issue Date FY: 2020 ( Subtotal = $469,863 ) |
| | 2020 | 2020 | CAMINO PHARMA, LLC | 7161 ROCK VALLEY CT | SAN DIEGO | CA | 92122-2737 | SAN DIEGO | USA | R43MH122063 | Negative Allosteric Modulators (NAMs) of Metabotropic Glutamate Receptors 2 & 3 (mGlu2/3) for the Treatment of Depression | 000 | 1 | NIH | 6/5/2020 | $469,863 |
|
|
